Financing (Tables)

12 Months Ended

Dec. 31, 2025

Debt Disclosure [Abstract]

Components of Debt

The components of the Company’s debt as of December 31 were as follows (amounts in millions):

	Outstanding Amount
Description and Aggregate Principal Amount	2025		2024
Euro-denominated commercial paper (€933 million and €931 million, respectively)(a)	$	1,097	$	965
3.35% senior unsecured notes due 9/15/2025 ($500 million) (the “2025 U.S. Notes”)(b)	—		500
0.2% senior unsecured notes due 3/18/2026 (€1.3 billion) (the “2026 Biopharma Euronotes”)(c)	1,469		1,293
2.1% senior unsecured notes due 9/30/2026 (€800 million) (the “2026 Euronotes”)(b)	940		828
0.4773% senior unsecured bonds due 4/9/2027 (CHF 250 million) (the “2027 CHF Bonds”)(d)	315		—
0.3% senior unsecured notes due 5/11/2027 (¥30.8 billion) (the “2027 Yen Notes”)(e)	196		195
1.2% senior unsecured notes due 6/30/2027 (€600 million) (the “2027 Euronotes”)(f)	704		620
0.45% senior unsecured notes due 3/18/2028 (€1.3 billion) (the “2028 Biopharma Euronotes”)(c)	1,466		1,291
1.125% senior unsecured bonds due 12/08/2028 (CHF 210 million) (the “2028 CHF Bonds”)(d)	267		233
0.8875% senior unsecured bonds due 10/10/2029 (CHF 325 million) (the “2029 CHF Bonds”)(d)	409		—
2.6% senior unsecured notes due 11/15/2029 ($800 million) (the “2029 Biopharma Notes”)(c)	798		797
2.5% senior unsecured notes due 3/30/2030 (€800 million) (the “2030 Euronotes”)(b)	940		829
0.75% senior unsecured notes due 9/18/2031 (€1.8 billion) (the “2031 Biopharma Euronotes”)(c)	2,050		1,805
0.65% senior unsecured notes due 5/11/2032 (¥53.2 billion) (the “2032 Yen Notes”)(e)	339		337
1.265% senior unsecured bonds due 10/10/2033 (CHF 325 million) (the “2033 CHF Bonds”)(d)	408		—
1.6249% senior unsecured bonds due 10/9/2037 (CHF 225 million) (the “2037 CHF Bonds”)(d)	282		—
1.35% senior unsecured notes due 9/18/2039 (€1.3 billion) (the “2039 Biopharma Euronotes”)(c)	1,456		1,282
3.25% senior unsecured notes due 11/15/2039 ($900 million) (the “2039 Biopharma Notes”)(c)	892		892
4.375% senior unsecured notes due 9/15/2045 ($500 million) (the “2045 U.S. Notes”)(b)	500		499
1.94% senior unsecured bonds due 10/10/2045 (CHF 125 million) (the “2045 CHF Bonds”)(d)	157		—
1.8% senior unsecured notes due 9/18/2049 (€750 million) (the “2049 Biopharma Euronotes”)(c)	873		769
3.4% senior unsecured notes due 11/15/2049 ($900 million) (the “2049 Biopharma Notes”)(c)	891		890
2.6% senior unsecured notes due 10/01/2050 ($1.0 billion) (the “2050 U.S. Notes”)(b)	983		982
2.8% senior unsecured notes due 12/10/2051 ($1.0 billion) (the “2051 U.S. Notes”)(b)	985		985
Other	1		13
Total debt	18,418		16,005
Less: currently payable	(2)		(505)
Long-term debt	$	18,416	$	15,500

(a) Issued by Danaher Corporation or DH Europe Finance II S.a.r.l. (“Danaher International II”).

(b) Issued by Danaher Corporation.

(c) Issued by Danaher International II.

(d) Issued by DH Switzerland Finance S.a.r.l. (“Danaher Switzerland”).

(e) Issued by DH Japan Finance S.a.r.l. (“Danaher Japan”).

(f) Issued by DH Europe Finance S.a.r.l. (“Danaher International”).

The following summarizes the key terms of the offering in aggregate:

	Aggregate Principal Amount (in millions)	Stated Annual Interest Rate		Maturity Date	Interest Payment Dates (in arrears)
2027 CHF Bonds	CHF 250	0.4773	%	April 9, 2027	April 9
2029 CHF Bonds	CHF 325	0.8875	%	October 10, 2029	October 10
2033 CHF Bonds	CHF 325	1.265	%	October 10, 2033	October 10
2037 CHF Bonds	CHF 225	1.6249	%	October 9, 2037	October 9
2045 CHF Bonds	CHF 125	1.94	%	October 10, 2045	October 10
Total Swiss Bonds	CHF 1,250

Schedule of Maturities of Long-term Debt

The Company’s minimum principal payments for the next five years are as follows ($ in millions):

2026	$	2,410
2027	2,305
2028	1,726
2029	1,203
2030	935
Thereafter	9,839